Cargando…

The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of new diagnoses of pulmonary carcinoma. This study investigated the correlation between 18 F-fluorodeoxyglucose uptake in computerized tomography integrated positron emission tomography and tumor size, lymph node metastas...

Descripción completa

Detalles Bibliográficos
Autores principales: Özgül, Mehmet Akif, Kirkil, Gamze, Seyhan, Ekrem Cengiz, Çetinkaya, Erdoğan, Özgül, Güler, Yüksel, Mahmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816207/
https://www.ncbi.nlm.nih.gov/pubmed/24148271
http://dx.doi.org/10.1186/2049-6958-8-69
_version_ 1782477929357246464
author Özgül, Mehmet Akif
Kirkil, Gamze
Seyhan, Ekrem Cengiz
Çetinkaya, Erdoğan
Özgül, Güler
Yüksel, Mahmut
author_facet Özgül, Mehmet Akif
Kirkil, Gamze
Seyhan, Ekrem Cengiz
Çetinkaya, Erdoğan
Özgül, Güler
Yüksel, Mahmut
author_sort Özgül, Mehmet Akif
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of new diagnoses of pulmonary carcinoma. This study investigated the correlation between 18 F-fluorodeoxyglucose uptake in computerized tomography integrated positron emission tomography and tumor size, lymph node metastasis, and distant metastasis in patients with NSCLC. METHODS: The records of 151 NSCLC patients (139 male, 12 female; mean age 59.60 years) were evaluated retrospectively. RESULTS: Forty-one cases were adenocarcinomas; 45 squamous cell carcinomas; and 65 unspecified NSCLC. When the cases were categorized according to tumor size (group 1, ≤ 3 cm; group 2, > 3 and ≤ 5 cm; group 3, > 5 cm), the maximum standardized uptake value (SUVmax) was significantly lower in groups 1 and 2 compared with group 3 (p = 0.006 for each). Considering all cases, tumor SUVmax was not correlated with age, gender, or histopathological type. Lymph node metastases were pathologically proven in 24 cases: 24% of these were adenocarcinomas, 6% squamous cell carcinomas, and 16% unspecified NSCLC. Neither lymph node involvement nor distant metastases were correlated with tumor SUVmax, although lymph node size was positively correlated with lymph node SUVmax (r = 0.775; p < 0.001). CONCLUSIONS: SUVmax was significantly associated with tumor size, but not with distant metastases or lymph node involvement. Therefore, SUVmax on positron emission tomography is not predictive of the presence of metastases.
format Online
Article
Text
id pubmed-3816207
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38162072013-11-04 The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer Özgül, Mehmet Akif Kirkil, Gamze Seyhan, Ekrem Cengiz Çetinkaya, Erdoğan Özgül, Güler Yüksel, Mahmut Multidiscip Respir Med Original Research Article BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of new diagnoses of pulmonary carcinoma. This study investigated the correlation between 18 F-fluorodeoxyglucose uptake in computerized tomography integrated positron emission tomography and tumor size, lymph node metastasis, and distant metastasis in patients with NSCLC. METHODS: The records of 151 NSCLC patients (139 male, 12 female; mean age 59.60 years) were evaluated retrospectively. RESULTS: Forty-one cases were adenocarcinomas; 45 squamous cell carcinomas; and 65 unspecified NSCLC. When the cases were categorized according to tumor size (group 1, ≤ 3 cm; group 2, > 3 and ≤ 5 cm; group 3, > 5 cm), the maximum standardized uptake value (SUVmax) was significantly lower in groups 1 and 2 compared with group 3 (p = 0.006 for each). Considering all cases, tumor SUVmax was not correlated with age, gender, or histopathological type. Lymph node metastases were pathologically proven in 24 cases: 24% of these were adenocarcinomas, 6% squamous cell carcinomas, and 16% unspecified NSCLC. Neither lymph node involvement nor distant metastases were correlated with tumor SUVmax, although lymph node size was positively correlated with lymph node SUVmax (r = 0.775; p < 0.001). CONCLUSIONS: SUVmax was significantly associated with tumor size, but not with distant metastases or lymph node involvement. Therefore, SUVmax on positron emission tomography is not predictive of the presence of metastases. BioMed Central 2013-10-22 /pmc/articles/PMC3816207/ /pubmed/24148271 http://dx.doi.org/10.1186/2049-6958-8-69 Text en Copyright © 2013 Özgül et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Özgül, Mehmet Akif
Kirkil, Gamze
Seyhan, Ekrem Cengiz
Çetinkaya, Erdoğan
Özgül, Güler
Yüksel, Mahmut
The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
title The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
title_full The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
title_fullStr The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
title_full_unstemmed The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
title_short The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
title_sort maximum standardized fdg uptake on pet-ct in patients with non-small cell lung cancer
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816207/
https://www.ncbi.nlm.nih.gov/pubmed/24148271
http://dx.doi.org/10.1186/2049-6958-8-69
work_keys_str_mv AT ozgulmehmetakif themaximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT kirkilgamze themaximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT seyhanekremcengiz themaximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT cetinkayaerdogan themaximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT ozgulguler themaximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT yukselmahmut themaximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT ozgulmehmetakif maximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT kirkilgamze maximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT seyhanekremcengiz maximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT cetinkayaerdogan maximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT ozgulguler maximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer
AT yukselmahmut maximumstandardizedfdguptakeonpetctinpatientswithnonsmallcelllungcancer